Skip to main
NTLA
NTLA logo

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics (NTLA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Intellia Therapeutics is positioned favorably due to its robust gene editing pipeline focused on high unmet medical needs, evidenced by a net present value of $12.22 per share for its lonvo-z asset in hereditary angioedema (HAE), with a projected launch in 2027 and significant market uptake anticipated by 2035. The company benefits from strategic collaborations with established pharmaceuticals like Regeneron and Novartis, enhancing its development capacity and market reach. Furthermore, a model indicating a gradual reduction in operating expenses, from $600 million to $150 million by 2034, suggests an efficient pathway to profitability as the pipeline matures beyond key Phase 3 trials.

Bears say

Intellia Therapeutics faces a negative outlook largely due to reduced market penetration expectations for gene editing therapies, modified from 4.8% to 3.2% for ATTR-CM, primarily influenced by concerns over liver enzyme and bilirubin elevations. The company is at risk of downward revisions in financial projections and price targets if its products do not gain regulatory approval, particularly amidst rising competitive pressures from stabilizers and RNAi therapies. Additionally, the inherent unpredictability of drug development, combined with potential clinical trial failures, heightens the risk of a loss of investor confidence in both Intellia and the broader CRISPR/Cas9 technology, which could lead to significant volatility in stock performance.

Intellia Therapeutics (NTLA) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Intellia Therapeutics (NTLA) Forecast

Analysts have given Intellia Therapeutics (NTLA) a Buy based on their latest research and market trends.

According to 19 analysts, Intellia Therapeutics (NTLA) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Intellia Therapeutics (NTLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.